| |
|
|
|
|
|
 |
| |
|
¸ÞÅä·»¿¬°í0.3%(¸ÞÅå»ç·») METOLEN OINT.[Methoxsalen]
|
|
Àü¹®ÀǾàǰ | »èÁ¦
|
|
|
| |
 |
¾Ë¸²: |
µå·°ÀÎÆ÷¿¡¼´Â ÀǾàǰ ÀÎÅÍ³Ý ÆÇ¸Å¸¦ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
|
Àü¹®/ÀÏ¹Ý |
Àü¹®
|
|
Á¦Á¶È¸»ç |
Á¦ÀÌ´õºíÀ¯½Å¾à(ÁÖ)
|
ÆÇ¸Åȸ»ç |
Á¦ÀÌ´õºíÀ¯½Å¾à(ÁÖ)
|
Çã°¡Á¤º¸ |
ÃëÇÏ
(2021.07.01)
|
BIT ¾àÈ¿ºÐ·ù |
±âŸ ÇǺΠ& Á¡¸· °ü·Ã ¾à¹° (Other Skin & Mucous Membrane Related Agents)
|
º¹ÁöºÎºÐ·ù |
269[±âŸÀÇ ¿ÜÇÇ¿ë¾à ] |
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå |
644100220[A21950721] \0 ¿ø/1g(2016.10.01)(ÇöÀç¾à°¡)\196 ¿ø/1g(2014.02.01) (º¯°æÀü¾à°¡)
|
|
|
ATCÄÚµå |
Methoxsalen / D05AD02 |
NDCÄÚµå |
[Proprietary Name Search _ ƯÇãµî·Ï¸í,»óÇ¥¸íÀ¸·Î °Ë»ö]
[Active Ingredient Search _ ÁÖ¼ººÐÀ¸·Î °Ë»ö]
[NDC Number Search _ NDCÄÚµå·Î °Ë»ö]
|
¼ººÐ / ÇÔ·® |
[½ÉÆò¿ø ÁÖ¼ººÐÄÚµå ±âÁØ ¼ººÐÇÔ·®Á¤º¸ Á¶È¸]

|
÷°¡Á¦ |
µð¿¤ÇǷθ®µ·Ä«¸£º»»ê³ªÆ®·ý¾×,
¶ó¿ì¸±È²»ê³ªÆ®·ý,
¼¼Æ¿¾ËÄÚ¿Ã,
¼Ò¸£ºñź¸ð³ë½ºÅ׾Ʒ¹ÀÌÆ®,
½ºÅ׾Ƹ±¾ËÄÚ¿Ã,
À¯µ¿ÆÄ¶óÇÉ,
Á¤Á¦¼ö,
Ä«º¸¸Ó940,
Æ®¸®¿¡Åº¿Ã¾Æ¹Î,
ÆÄ¶ó¿Á½Ã¾È½ÄÇâ»ê¸ÞÄ¥,
ÆÄ¶ó¿Á½Ã¾È½ÄÇâ»êÇÁ·ÎÇÊ
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
À¯·áȸ¿ø °áÀç½Ã¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸¸¦
ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
À¯·áÁ¤º¸¸ñ·ÏÀº Àü¹®È¸¿øÀ¸·Î
·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
|
|
|
 | Çã°¡Á¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇÑ±Ý¾× |
644100220[A21950721]
[º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸]
\0 ¿ø/1g(2016.10.01)(ÇöÀç¾à°¡)
\196 ¿ø/1g(2014.02.01)(º¯°æÀü¾à°¡)
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁ¶È¸]
|
| ºü¸¥Á¶È¸ |
|
| Á¦Ç°¼º»ó |
¹é»öÀÇ ¿¬°íÁ¦ [Á¦ÇüÁ¤º¸ È®ÀÎ] |
| Æ÷À塤À¯Åë´ÜÀ§ |
10g
|
| Æ÷À塤ÄÚµå´ÜÀ§ |
| ¾àǰ±Ô°Ý |
´ÜÀ§ |
Æ÷ÀåÇüÅ |
´ëÇ¥ÄÚµå |
Ç¥ÁØÄÚµå |
ºñ°í |
| 10±×·¥ |
1 °³ |
Æ©ºê |
8806441002205 |
8806441002229 |
ºñ¸Åǰ |
| 10±×·¥ |
1 °³ |
Æ©ºê |
8806441002205 |
8806441002212 |
|
|
| ÁÖ¼ººÐÄÚµå |
192202COM
[µ¿ÀÏÇÑ ÁÖ¼ººÐÄڵ带 °¡Áø ¿À¸®Áö³¯ ¶Ç´Â Á¦³×¸¯ ÀǾàǰ Á¶È¸]
|
| Çã°¡»çÇ× ¿ø¹®Á¶È¸ |
[Çã°¡»çÇ× ¿ø¹®Á¶È¸]
|
| È¿´ÉÈ¿°ú |
[ÀûÀÀÁõ º° °Ë»ö]
½É»ó¼º¹é¹Ý(º¸Åë¹é¹Ý)
|
| ¿ë¹ý¿ë·® |
* Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù.
[󹿾à¾î]
¡¤ÀÇ»çÀÇ Áö½Ã¿¡ µû¶ó ȯºÎ¿¡¸¸ Àû·®À» ¹Ù¸£°í, 1-2½Ã°£ ÈÄ¿¡ Àϱ¤¿åÀ» Çϰųª ÀΰøÀڿܼ±À» Á¶»çÇÑ´Ù. µ¿ÀÏ È¯ºÎ¿¡ º¸Åë ÁÖ 1-3ȸ Á¤µµÀÇ Ä¡·á°¡ ¹Ù¶÷Á÷ÇÏ´Ù. ±¹ÇѼº ¹é¹Ý¿¡´Â ¿Ü¿ë¿ä¹ýÀÌ ¹Ù¶÷Á÷ÇÏ´Ù.
|
| ±Ý±â |
1) Æ÷¸£ÇǸ°Áõ, È«¹Ý¼º·çǪ½º, »ö¼Ò¼º°ÇÇÇÁõ, ´ÙÇü ±¤¹ßÁø µîÀÇ ±¤°ú¹ÎÁõÀ» ¼ö¹ÝÇϴ ȯÀÚ(±¤µ¶¼º¹ÝÀÀÀÌ Áõ°µÉ ¼ö ÀÖ´Ù)
2) ÇÇºÎ¾Ï ¶Ç´Â ±× º´·ÂÀÌ Àִ ȯÀÚ(ÇǺξÏÀÌ ¾ÇÈ ¶Ç´Â Àç¹ßÇÒ ¼ö ÀÖ´Ù) |
| ½ÅÁßÅõ¿© |
¾à¹°¿¡ ÀÇÇÑ ±¤°ú¹ÎÁõ ¶Ç´Â ±× º´·ÂÀÌ Àִ ȯÀÚ(±¤°ú¹ÎÁõÀÌ Áõ°µÉ ¼ö ÀÖ´Ù) |
| ÀÌ»ó¹ÝÀÀ |
1) °ú·® »ç¿ë½Ã ¶Ç´Â Àڿܼ±ÀÇ °úÀ×Á¶»ç¿¡ µû¶ó Á¾Ã¢, ¼öÆ÷, ¹ßÀû µîÀÇ Áõ»óÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¹Ç·Î ÀÌ·¯ÇÑ °æ¿ì¿¡´Â Ä¡·á¸¦ ÁßÁöÇÑ´Ù. Ä¡·á¸¦ Àç°³ÇÏ´Â °æ¿ì¿¡´Â Àڿܼ± Á¶»ç·® À» ÁÙÀδÙ.
2) ¶§¶§·Î ÇǺο°, °¡·Á¿ò, È«Á¶, Àμ³, °¡Çǰ¡ ¹ß»ýÇÒ ¼ö ÀÖ´Ù.
|
| »óÈ£ÀÛ¿ë |
´ÙÀ½ÀÇ ¾à¹°°ú À½½Ä¹°Àº ÇǺÎÀÇ ±¤°ú¹ÎÁõÀ» Áõ°¡½Ã۸ç, ƯÈ÷ ÀåÆÄÀåÀÇ Àڿܼ±(UVA)¿¡ ´ëÇÑ °ú¹ÎÁõÀ» Áõ°¡½ÃÄѼ ¾àÈ¿¸¦ ³ªÅ¸³»¹Ç·Î, ÀÌ ¾à°ú º´¿ë½Ã ±¤µ¶¼ºÀ» Áõ°¡½Ãų ¼ö ÀÖ´Ù.
1) ±¤°ú¹ÎÁõÀ» ÀÏÀ¸Å²´Ù°í ¾Ë·ÁÁø ¾à¹° : Äû³î·Ð°è ¾à¹°(³¯¸®µð½Ä»ê, ¿ÀÇ÷ϻç½Å, ½ºÆÄÇ÷ϻç½Å µî), Åׯ®¶ó»çÀÌŬ¸°°è ¾à¹°(¿°»ê¹Ì³ë»çÀÌŬ¸°, ¿°»êµ¶½Ã»çÀÌŬ¸° µî), ¼³ÆÄÁ¦, ±× ¸®¼¼¿ÀÇ®ºó, Ÿ¸£Á¦Á¦, Ä¡¾ÆÁþ°è ¾à¹°(¿¡Ä¡¾ÆÁþ, »çÀÌŬ·Îº¥Ä¡¾ÆÁþ, ÆæÇÃ·çÆ¼Áþ µî), Æ÷¸£ ÇǸ°°è ¾à¹°(NAPP µî), Æä³ëÄ¡¾ÆÁø°è ¾à¹°(ÇÁ·ÎŬ·Î¸£Æä¶óÁø, Ŭ·Î¸£ÇÁ·Î¸¶Áø µî), ¸Þ Ä¥·»ºí·ç µî
2) Ǫ·ÎÄí¸¶¸°À» ÇÔÀ¯ÇÑ À½½Ä¹° : ¼¿·¯¸®, ¶óÀÓ, ´ç±Ù, ÆÄ¼¼¸®, ¹«È°ú, °ÜÀÚ µî |
| Related FDA Approved Drug |
|
|
|
 | Á¤º¸¿ä¾à |
|
|
|
µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
|
|
 | ÄÚµå ¹× ºÐ·ùÁ¤º¸ |
|
|
| |
|
 | Á¦Ç°Á¤º¸ |
|
|
|
|
 | º¹¾àÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| LACTmed ¹Ù·Î°¡±â |
[¹Ù·Î°¡±â]
|
| ¾à¸®ÀÛ¿ë |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| ÀӺο¡´ëÇÑÅõ¿© |
| * |
ÀüüÀӽŠ±â°£º°·Î ¿©·¯µî±ÞÀÌ Á¸ÀçÇÒ ¼ö ÀÖÀ¸¸ç °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ º¸¿©Áý´Ï´Ù. ´Ü, º¹ÇÕÁ¦ÀÇ °æ¿ì ¸ðµç º¹ÇÕÁ¦¼ººÐ¿¡ ´ëÇÑ ÀÓºÎÅõ¿©µî±ÞÀÌ Ç¥½ÃµÈ°ÍÀº Àý´ë ¾Æ´Ï¸ç Ç¥½ÃµÈ°ÍÁß¿¡ °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ ³ªÅ¸³³´Ï´Ù.
|
|
|   |
 FDA : Cµî±Þ
|
|
| * |
»ó±â ÀÓºÎÅõ¿©¿¡ ´ëÇÑ Á¤º¸´Â Àü»êó¸® µÇ¸é¼ ÀÔ·Â ¿À·ù °¡´É¼ºÀÌ Á¸ÀçÇÕ´Ï´Ù. ¿À·ù °¡´É¼ºÀ» ÃÖ¼ÒÈÇϱâ À§ÇÏ¿© ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖÀ¸³ª, ±× Á¤È®¼º¿¡ ´ëÇÏ¿© È®½ÅÀ» µå¸± ¼ö ¾ø½À´Ï´Ù. ÀÌ¿¡ ´ëÇØ ȸ»ç´Â Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù.
|
| * |
¹Ýµå½Ã °ø½Å·Â ÀÖ´Â ¹®ÇåÀ» ´Ù½Ã Çѹø Âü°í ÇϽñ⠹ٶó¸ç ÀÇ»ç ¶Ç´Â ¾à»çÀÇ ÆÇ´Ü¿¡ µû¶ó Åõ¿©¿©ºÎ°¡ °áÁ¤µÇ¾î¾ß ÇÕ´Ï´Ù.
|
|
|
| Pharmacokinetics |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸ |
[º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸]
|
| Á¦Çüº° º¹¾àÁöµµ |
[¿¬°í] |
| º¸°ü»ó ÁÖÀÇ |
|
| Á¶Á¦½Ã ÁÖÀÇ |
|
|
|
 | ½É»çÁ¤º¸ |
|
|
|
|
 | ÇмúÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| DUR (ÀǾàǰ»ç¿ëÆò°¡) |
º´¿ë±Ý±â :
°í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]
¿¬·É´ë±Ý±â :
°í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
|
| Mechanism of Action |
Methoxsalen¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ After activation it binds preferentially to the guanine and cytosine moieties of DNA, leading to cross-linking of DNA, thus inhibiting DNA synthesis and function.
|
| Pharmacology |
Methoxsalen¿¡ ´ëÇÑ Pharmacology Á¤º¸ Methoxsalen selectively inhibits the synthesis of deoxyribonucleic acid (DNA). The guanine and cytosine content correlates with the degree of Methoxsalen-induced cross-linking. At high concentrations of the drug, cellular RNA and protein synthesis are also suppressed.
|
| Metabolism |
Methoxsalen¿¡ ´ëÇÑ Metabolism Á¤º¸ # Phase_1_Metabolizing_Enzyme:Cytochrome P450 2A6 (CYP2A6)
|
| Protein Binding |
Methoxsalen¿¡ ´ëÇÑ ´Ü¹é°áÇÕ Á¤º¸ Not Available
|
| Half-life |
Methoxsalen¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ Approximately 2 hours
|
| Absorption |
Methoxsalen¿¡ ´ëÇÑ Absorption Á¤º¸ Not Available
|
| Pharmacokinetics |
MethoxsalenÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
- ÃÖ´ëÈ¿°ú ¹ßÇö½Ã°£ : °æ±¸ : ±¤°ú¹Î¼º : 1.5-3 ½Ã°£
- ÀÛ¿ëÁö¼Ó½Ã°£ : °æ±¸ : ±¤°ú¹Î¼º : 8½Ã°£
- Èí¼ö : À½½Ä¹°¿¡ ÀÇÇØ Ç÷ÁßÃÖ°í³óµµ°¡ Áõ°¡ÇÑ´Ù.
- Ç÷ÁßÃÖ°í³óµµ µµ´Þ½Ã°£ : 2-4 ½Ã°£
- ¼Ò½Ç : 24½Ã°£ À̳»¿¡ 90-95%°¡ ´ë»çü·Î ½Å¹è¼³µÈ´Ù. 4-10%´Â º¯¹è¼³µÈ´Ù.
|
| Biotransformation |
Methoxsalen¿¡ ´ëÇÑ Biotransformation Á¤º¸ Not Available
|
| Toxicity |
Methoxsalen¿¡ ´ëÇÑ Toxicity Á¤º¸ Not Available
|
| Drug Interactions |
Methoxsalen¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Ethotoin The hydantoin decreases the effect of psoraleneFosphenytoin The hydantoin decreases the effect of psoraleneMephenytoin The hydantoin decreases the effect of psoralenePhenytoin The hydantoin decreases the effect of psoralene
|
CYP450 Drug Interaction |
[CYP450 TableÁ÷Á¢Á¶È¸]
|
| Food Interaction |
Methoxsalen¿¡ ´ëÇÑ Food Interaction Á¤º¸ Take with food or milk, or in two divided doses 30 minutes apart to decrease nausea.
|
| Drug Target |
[Drug Target]
|
| Description |
Methoxsalen¿¡ ´ëÇÑ Description Á¤º¸ A naturally occurring furocoumarin compound found in several species of plants, including Psoralea corylifolia. It is a photoactive substance that forms DNA adducts in the presence of ultraviolet A irradiation. [PubChem]
|
| Dosage Form |
Methoxsalen¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Capsule OralLiquid TopicalLotion Topical
|
| Drug Category |
Methoxsalen¿¡ ´ëÇÑ Drug_Category Á¤º¸ Antineoplastic AgentsCross-Linking ReagentsPhotosensitizing AgentsPigmenting Agents
|
| Smiles String Canonical |
Methoxsalen¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ COC1=C2OC(=O)C=CC2=CC2=C1OC=C2
|
| Smiles String Isomeric |
Methoxsalen¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ COC1=C2OC(=O)C=CC2=CC2=C1OC=C2
|
| InChI Identifier |
Methoxsalen¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C12H8O4/c1-14-12-10-8(4-5-15-10)6-7-2-3-9(13)16-11(7)12/h2-6H,1H3
|
| Chemical IUPAC Name |
Methoxsalen¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ 9-methoxyfuro[3,2-g]chromen-7-one
|
|
|
 | »ç¿ëÀÚÄÁÅÙÃ÷ |
|
|
|
|
|
-
ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2024-09-07
-
º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
|
|
¾Ë¸² |
»ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù. |
|
°æ°í |
µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù.
Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â
Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡±¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
|
|
¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é
¿©±â·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ
[ÀǾàǰº´¿ë/¿¬·É´ë±Ý±â °í½Ã±Ù°Å·Î ¹Ù·Î°¡±â] Á¦¸ñ ¾øÀ½
2008³â 8¿ù 1ÀÏ ¾à°¡ÈÀÏ»ó 8¿ù´Þ ½Å±ÔµîÀç ¹× »èÁ¦µÇ´Â ǰ¸ñ Æ÷ÇÔÇÑ º´¿ë¿¬·É ±Ý±â ǰ¸ñ¸®½ºÆ® ±âÁØ
1. ÇöÀç °Ë»öÇÑ Á¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â Á¦Ç° Á¸Àç¿©ºÎ ¹× °Ë»ö
ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 Á¦Ç°³»¿ª °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
2. ¿¬·É´ë±Ý±â Á¸Àç¿©ºÎ
ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ ¿¬·É±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
|
|
|
|